Fulcrum Therapeutics/$FULC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Fulcrum Therapeutics
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Ticker
$FULC
Sector
Primary listing
Employees
55
Headquarters
Website
FULC Metrics
BasicAdvanced
$558M
-
-$1.18
3.18
-
Price and volume
Market cap
$558M
Beta
3.18
52-week high
$15.74
52-week low
$2.32
Average daily volume
850K
Financial strength
Current ratio
27.397
Quick ratio
27.083
Long term debt to equity
1.157
Total debt to equity
1.846
Profitability
EBITDA (TTM)
-83.379
Management effectiveness
Return on assets (TTM)
-16.90%
Return on equity (TTM)
-25.30%
Valuation
Price to book
1.6
Price to tangible book (TTM)
1.6
Price to free cash flow (TTM)
-8.793
Free cash flow yield (TTM)
-11.37%
Free cash flow per share (TTM)
-0.953
Growth
Earnings per share change (TTM)
653.31%
3-year earnings per share growth (CAGR)
-21.49%
What the Analysts think about FULC
Analyst ratings (Buy, Hold, Sell) for Fulcrum Therapeutics stock.
FULC Financial Performance
Revenues and expenses
FULC Earnings Performance
Company profitability
FULC News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fulcrum Therapeutics stock?
Fulcrum Therapeutics (FULC) has a market cap of $558M as of March 01, 2026.
What is the P/E ratio for Fulcrum Therapeutics stock?
The price to earnings (P/E) ratio for Fulcrum Therapeutics (FULC) stock is 0 as of March 01, 2026.
Does Fulcrum Therapeutics stock pay dividends?
No, Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders as of March 01, 2026.
When is the next Fulcrum Therapeutics dividend payment date?
Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders.
What is the beta indicator for Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) has a beta rating of 3.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.